Expansion of the secondary injury following primary spinal cord injury is a major pathological event that increases destruction in the spinal cord, so measures to reduce secondary injury are needed. Our previous study demonstrated that, at the front of the expanding secondary injury in the spinal cord, there is an ischemic area in which many neurons can still be rescued. Therefore, enhancement of blood circulation in the cord may be helpful, and indeed, we found that a traditional Chinese medicine, shu-xue-tong, efficiently reduces the secondary injury. The aim of the present study was to investigate the effect of reducing fibrinogen with Batroxobin, a drug widely used clinically for ischemia, in rats with spinal cord contusion. We found that both 2 and 4 Batroxobin units (BU)/kg efficiently decreased the plasma fibrinogen, and 2 BU/kg significantly increased spinal blood flow, enhanced neuronal survival, mitigated astrocyte and microglia activation, and improved locomotor recovery. However, 4 BU/kg had no effect on the secondary spinal cord injury. These data suggest that Batroxobin has multiple beneficial effects on spinal cord injury, indicating a potential clinical application.
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INtrODUctION
Spinal cord injury (SCI) is a serious problem and has been intensively studied [1] . Secondary injury after primary spinal cord damage plays an important role in the final outcome. Pathological vascular changes and the subsequent events are crucial for the development of secondary injury [2] [3] [4] . Destruction of the blood-spinal cord barrier leads to massive leakage of blood components, initiating inflammation and gliosis [5] . Post-traumatic ischemia resulting from tissue compression, thrombosis and vasospasm causes progressive neuronal death, and shows a direct linear relationship with the severity of injury [6] [7] [8] . Our previous study has shown that two ischemic zones occur at the front of the expanding secondary injury.
In the zone adjacent to the injury, most of the neurons have degenerated or disappeared, whereas in the farther zone, although there are clear signs of ischemia, the morphology of the Nissl bodies appears not much changed, indicating that these neurons can be rescued by improving the blood flow [9] . This explains the finding by Johnson et al. that fluarizine, a vasodilator, ameliorates ischemia in the cord and enhances neurological recovery in rabbits [10] . Thus, enhancement of blood flow in the cord could be an efficient strategy for decreasing secondary injury. Our subsequent study using a traditional Chinese medicine, shu-xue-tong,
which promotes blood flow, demonstrated the efficacy of this strategy [11] . Therefore, in this study, we further investigated the possibility of making use of innate bloodborne factors.
Fibrinogen is a 340-kDa protein secreted by hepatocytes and is present in the blood at a high concentration. Upon activation of the coagulation cascade, both the α and β chains of fibrinogen are cleaved by with platelets, accomplishes the process of blood clotting [12] .
Furthermore, recent studies reported that fibrinogen leaking from ruptured blood vessels triggers the activation of astrocytes [13] and microglia [14] , suggesting its involvement in the development of secondary SCI.
Batroxobin is a thrombin-like serine protease from the venom of the snake Bothrops moojeni. In contrast to thrombin, Batroxobin only cleaves the α chain of fibrinogen, resulting in the production of a fibrin monomer, which has poorer linking ability than the polymer and thus decreases the blood fibrinogen and promotes blood flow [15] . Therefore, Batroxobin has been successfully used in various ischemic disorders, such as stroke, deep-vein thrombosis, myocardial infarction, peripheral arterial thrombosis, and sudden deafness [16] [17] [18] . Its effect on SCI, however, has not been studied. Given the important role fibrinogen plays in the pathology of SCI, the present study was designed to investigate whether Batroxobin has a beneficial effect on SCI in rats and its possible clinical application.
MAtErIALs AND MEtHODs

Animal Model
All the animal experiments were approved by the Animal forceps lateral crush SCI model [19] . Because it is difficult to manually ensure vertical orientation of the forceps and equal degrees of compression bilaterally, we designed a mechanical version in which a pair of forceps was mounted on a stereotaxic device and its two blades could be closed simultaneously from both sides. After exposure of the dura mater, the forceps were first pressed until their tips met, then lowered and aligned with the midline of the cord.
Then the blades were spread, lowered along both sides of the cord for the desired distance, closed to a preset gap between the blades (0.5 mm), and compression maintained for 20 s.
Batroxobin Administration
According to the supplier's instructions (DF-521, Tobishi), Batroxobin is recommended to be administered once every other day. Considering the drastic changes that occur right after the injury, particularly the spread of bleeding, we expected that 12 h after injury was needed for the changes to stabilize. Our pilot experiment showed that by that time the hemorrhage had stopped, with only a little fresh bleeding. Since Batroxobin does not enhance bleeding [15] ,
we injected it at 12 h, 3 days and 5 days after SCI via the tail vein. Saline was injected as the control.
Plasma Fibrinogen Assay
Two hours after the last dose of Batroxobin, blood samples were collected for a coagulation test (n = 4/group). The concentration of fibrinogen was determined using an Automated Coagulation Analysis Instrument (STA Compact, Stago Co., France).
Laser-Doppler Flowmetry
Spinal cord blood flow was measured 2 h after the last 
Immunohistochemistry and Morphological Analysis
At 7 days post-SCI, after behavioral analysis, the 
Footprint Analysis
Footprint analysis was conducted 1 day before and 7 days after SCI. The plantar surface of both hindlimbs of each rat was colored black and the dorsal surface red with non-toxic ink. The rats were then allowed to run on a white paper (89.1 cm × 10.5 cm); the red and/or black ink printed onto the paper was considered as one set of footprints. Stride length (SL) was defined as the distance between the centers of adjacent footprints. The SL of both hindlimbs was measured and the average of 5-8 SLs from each rat was used. The stride length factor (SLF) was calculated as SLF = (SL pre-SCI −SL post-SCI )/SL pre-SCI and was used for statistical analysis.
statistical Analysis
All the morphological measurements were made using Adobe Photoshop CS3, and all data were analyzed by SPSS l6.0 (Chicago, IL). Data are presented as mean ± SEM, and were analyzed with one-way ANOVA, followed by Dunnett's post hoc test, except for BBB scoring which was further analyzed by the Bonferroni post hoc test as recommended [20] . P <0.05 was considered statistically significant. (Fig. 2D) . Moreover, 2 BU/kg reduced the lesion area by 23.54 ± 2.12%, while 4 BU/kg did not (Fig. 2E) . These results indicated that 2 BU/kg, but not 4 BU/kg, promoted the survival of neurons adjacent to the lesion and reduced the lesion size.
Since the neurons in zones 4 and 5 appeared normal, only zones 1-3 were investigated in the subsequent experiments.
Effects of Batroxobin on Astrocyte Activation
To assess the effects of Batroxobin on the activation of astrocytes, immunohistochemistry for GFAP and Neurocan (another marker of reactive astrocytes to support the results from GFAP staining) was performed. In saline controls, intense GFAP immunoreactivity was seen in zone 1, and this decreased from zones 1-3 (Fig. 3A) . But 2 BU/ kg decreased the IFI of GFAP by 60.06 ± 4.83% (n = 6 rats, P <0.05, Fig. 3B, D) . No significant change of GFAP immunoreactivity was found in the 4 BU/kg group (Fig. 3C,   D) . Further, the IFI of Neurocan was decreased by 75.22 ± 3.00% (P <0.01) in the 2 BU/kg group, and by 46.50 ± 6.71%
(P <0.01) in the 4 BU/kg group (n = 6 rats, Fig. 4 ). Taken together, these data suggested that 2 BU/kg alleviated the astrocyte activation.
Effects of Batroxobin on Microglia Activation
To define the effects of Batroxobin on the activation of microglia, immunostaining for Iba-1 was performed at 7 days post-SCI. In saline controls, numerous Iba-1 positive cells were found in zone 1 and decreased from zones 1-3
( Fig. 5A) . Measurement of the IFI of Iba-1 in the first three adjacent zones showed a reduction of 29.07 ± 7.83% in the 2 BU/kg group (n = 6 rats, P <0.05, Fig 5B, D) . But no significant reduction of Iba-1 IFI/area was found in the 4 UB/kg group (Fig. 5C, D) . These results suggested that 2 BU/kg effectively alleviated microglia activation.
Effects of Batroxobin on Locomotor recovery after scI
To test whether Batroxobin is beneficial to the functional recovery from SCI, we evaluated locomotion by BBB scoring and RHI assay at 1, 4 and 7 days after SCI, and the footprint test at 7 days after SCI. The BBB scores showed that at 4 and 7 days, 2 BU/kg-treated rats showed significant improvement (Fig. 6A) . Similarly, the 2 BU/kgtreated rats showed higher lift of the hind limbs at 4 and 7 days as evaluated by the RHI assay (Fig. 6B) . The SLF in the footprint test showed a 63.67 ± 12.1% decrease at 7 days in the 2 BU/kg group (n = 6 rats, P <0.05, Fig. 6C ).
However, 4 BU/kg did not have any significant effects on the BBB scores, RHI and SLF (Fig. 6) .
DIscUssION
SCI has a high incidence and is a major concern for society, patients, and their families. Among the various types of SCI, contusion has the highest incidence.
Fortunately, early surgical intervention is very successful [21] .
Following the primary spinal cord injury, secondary injury expands continuously for ~4 weeks, so understanding the mechanism and finding measures to control it are of great importance. Our previous study demonstrated that an ischemic zone occurs at the front of the expending secondary injury [9] , and this triggers the advance of the 
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injury. We further showed that enhancing spinal cord blood circulation indeed reduces the secondary injury [11] . Using the same strategy, here we studied the effect of Batroxobin, a drug widely used in various ischemic disorders [16] [17] [18] , in reducing the secondary SCI. Fibrinogen is a blood-borne molecule involved in both circulation and glial reaction after SCI [12] [13] [14] , and Batroxobin is a defibrinogating agent.
Moreover, Batroxobin decreases blood viscosity without affecting other coagulating proteins such as factors V, VIII and XIII, as well as platelets and endothelial cells [15] .
One of the concerns for Batroxobin administration in SCI is the possibility of inducing bleeding in the injured cord. It has been reported that its downstream product, fibrinopeptide-A, forms an unstable clot and even shortens the bleeding time in vivo [15, 22] . In the present study, we demonstrated that 2 BU/kg promoted neuronal survival, alleviated the activation of astrocytes and microglia, and improved locomotor recovery. But surprisingly, 4 BU/kg had no effect, neither good nor bad. In humans, only one dose is allowed on special occasions. Apparently, 4 BU/kg is an overdose in rats. The mechanisms of the null effect remain to be elucidated.
In conclusion, since Batroxobin is clinically widely used, its beneficial effects in reducing secondary spinal cord injury can be transplanted to the bedside.
